IN THE UNITED STATES PAT	IN THE UNITED STATES PATENT AND TRADEMARK OFFICE					
In re application of:) Examiner: Ohara, Eileen B.					
ASHKENAZI, et al.) Art Unit: 1646					
Application Serial No. 10/017,086	Confirmation No: 4093					
Filed: October 24, 2001) Attorney's Docket No. 39780-2630 P1C64					
For: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME) Customer No. 35489)))					

EXPRESS MAIL LABEL NO. EL 977 609 821 US

Date Mailed: NOVEMBER 18, 2004

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

MAIL STOP AMENDMENT

Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form Supplemental PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):					
	(1)	It is being filed within 3 months of the application filing date and is other continued prosecution application under § 1.53(d)			
	tilali a t	OR			
	(2)	It is being filed within 3 months of entry of a national stage OR			
	(3) merits	It is being filed before the mail date of the first Office Action on the			

		(4) of a red	OR It is being filed before the magnest for continued examination	nailing of a first Office Action after the filing on under § 1.114.		
	37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyon filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first C action on the merits, but before the mailing date of the earlier of a final office action under § or a notice of allowance under §1.311, then:					
		a certification a	as specified in §1.97(e) is pro	vided below; or		
	a fee of \$180.00 as set forth in \$1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.					
37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the office action under §1.113 or a notice of allowance under §1.311, but before pay fee, then:				fter the mailing date of the earlier of a final under §1.311, but before payment of the issue		
	A.	a certification a	as specified in §1.97(e) is con	npleted below; and		
	B.	a petition unde submitted here		ng consideration of this statement is		
	C.		0 as set forth in §1.17(i)(1) is other papers filed together w	authorized below, enclosed, or included with ith this statement.		
	Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees of \$180.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Attorney's Docket No. 39780-2630 P1C64).					
			Respectfull	y submitted,		
Dated:	Novem	ber 18, 2004	By: Anna L.	Barry (Reg. No. 51,436)		

HELLER EHRMAN WHITE & McAULIFFE LLP

275 Middlefield Road

Menlo Park, CA 94025-3506 Telephone: (650) 324-7000 Facsimile: (650) 324-0638

Form PTO-1449 ALEORMATION DISCLOSURE STATEMENT		Attorney's Docket No. 39780-2630 P1C64 Applicant(s) Application Serial No. 10/017,086									
MEO	RMATIC	ON DISCLOS	URE STATEMENT		ri J. ASHKENAZI	, et al.					
OR 8 NON (use several sheets if necessary)			if necessary)	Filing Date: October 24, 2001		Group Art Unit: 1646					
	0/		EX	U.S. PATENT DOCUMENTS							
Examinar Ref. Date Document No.		-4	Name	Class	Subclass	Filing Date (if appropr					
-		MUA	8 2004				<u></u>				
			FO	REIGN PATENT DOCUMENTS							
Examiner	Ref.	Date	ment No.	Name	Class	Subclass	Translation				
Initials	No.						YES	NO			
		•									
						<u> </u>					
	i.			OTHER DOCUMENTS							
			(including	author, title, date, pertinent pages,	, etc.)						
Examiner Initials	Ref. No.	Title									
	1.	Hanna, J.S., et al., "HER-2/neu Breast Cancer Predictive Testing", Oathology Associates Medical Laboratores, August (1999).									
	2.	Hyman, E., et al., "Impace of DNA Amplification on Gene Expression Patterns in Breast Cancer ^{1,2} ", <i>Cancer Research</i> – 62:6240-6245 (2002)									
3. Orntoft, T.F., et al., "Genome-wise Study of Gene Copy Numbers, Transcripts, and Protein Levels in Pair invasive and Invasive Human Transitional Cell Carcinomas", Molecular & Cellular Proteomics – 1:37-45					'-45 (2002)) -					
4. Pollack, J.R., et al., "Microarray A			R., et al., "Microarray A onal Program of Huma	nalysis Reveals a Major Direct Role of DNA Copy Number Alteration in the n Breast Tumors", <i>PNAS</i> – <u>99(20)</u> :12963-12968 (2002)							
		J									
			14877								
		·	<u> </u>			,					
		-				, "					

	 	1			<u></u>						
					·····	···	,				
		<u> </u>									
<u></u>						-					
	-										
ļ	 	 									
	 										
	11										

ĺ	EXAMINER:	DATE CONSIDERED:			
	EXAMINER: Initial if citation considered, whether or not the citation conf	forms with MPEP 609. Draw a line through the citation if not in			
	conformance and not considered. Include a copy of this form with next communication to applicant.				
	*If an asterisk is placed beside the reference number, a copy is not provide				

Tri an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d). SV 2081026 v1